S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)

Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

$11.36
+0.07 (+0.62%)
(As of 02/27/2024 ET)

Centessa Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$9.43
-17.00% Downside
High Forecast$15.00
Average Forecast$9.43
Low Forecast$5.00
TypeCurrent Forecast
2/27/23 to 2/27/24
1 Month Ago
1/28/23 to 1/28/24
3 Months Ago
11/29/22 to 11/29/23
1 Year Ago
2/27/22 to 2/27/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.43$9.43$9.43$5.75
Predicted Upside-17.00% Downside51.83% Upside51.83% Upside41.06% Upside
Get Centessa Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.


CNTA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Centessa Pharmaceuticals Stock vs. The Competition

TypeCentessa PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.67
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside-17.00% Downside1,862.45% Upside7.73% Upside
News Sentiment RatingVery Positive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$4.00 ➝ $11.00+65.91%
10/26/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$4.00 ➝ $8.00+28.21%
8/15/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$4.50 ➝ $5.00-24.47%
8/15/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$9.00 ➝ $10.00+51.06%
8/15/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$6.00 ➝ $11.00+66.16%
7/25/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$11.00 ➝ $15.00+122.55%
6/21/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/17/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$6.00+50.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:46 PM ET.












CNTA Price Target - Frequently Asked Questions

What is Centessa Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Centessa Pharmaceuticals stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for CNTA. The average twelve-month price prediction for Centessa Pharmaceuticals is $9.43 with a high price target of $15.00 and a low price target of $5.00. Learn more on CNTA's analyst rating history.

Do Wall Street analysts like Centessa Pharmaceuticals more than its competitors?

Analysts like Centessa Pharmaceuticals more than other Medical companies. The consensus rating score for Centessa Pharmaceuticals is 2.75 while the average consensus rating score for medical companies is 2.68. Learn more on how CNTA compares to other companies.

Does Centessa Pharmaceuticals's stock price have much upside?

According to analysts, Centessa Pharmaceuticals's stock has a predicted upside of 51.83% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:CNTA) was last updated on 2/27/2024 by MarketBeat.com Staff